Is metoprolol succinate safe to use in a patient with chronic obstructive pulmonary disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Metoprolol Succinate Can Be Used Cautiously in COPD Patients

Metoprolol succinate, a cardioselective beta-1 blocker, may be used with caution in patients with COPD when there is a clear cardiovascular indication, though it should not be prescribed solely for COPD management.

Key Clinical Context

The evidence presents an important distinction: while older COPD guidelines from 1997 stated that "beta-blocking agents (including eyedrop formulations) should be avoided" 1, this recommendation has been substantially revised based on newer evidence and understanding of cardioselective beta-blockers.

When Metoprolol Succinate Is Appropriate

Cardioselective beta-blockers like metoprolol succinate should be used when patients have:

  • Heart failure with reduced ejection fraction - The 2016 ESC guidelines explicitly state that "beta-blockers are only relatively contraindicated in asthma, but not in COPD" and recommend using cardioselective agents (bisoprolol, metoprolol succinate, or nebivolol) 2

  • Post-myocardial infarction - Recent evidence shows beta-blockers improve survival in COPD patients after first MI 3

  • Coronary artery disease, hypertension, or arrhythmias - A 2022 guideline emphasizes that COPD is not a contraindication and that beta-blockers reduce mortality in this population 4

Safety Profile

The FDA label for metoprolol succinate states: "PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1-selectivity, however, metoprolol succinate extended-release tablets may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment" 5.

Critical safety evidence:

  • A 2005 Cochrane review found that cardioselective beta-blockers produced no change in FEV1 or respiratory symptoms compared to placebo, even in patients with severe obstruction or reversible components 6

  • A 2010 crossover trial in 51 CHF patients (35 with COPD) showed that while carvedilol (nonselective) reduced FEV1 more than metoprolol or bisoprolol, all switches were well tolerated 7

  • A 2007 study demonstrated that metoprolol succinate did not deteriorate bronchial patency in COPD/asthma patients (baseline FEV1 81.08% vs. 84.58% at study end) 8

Important Limitation: No Benefit Without Cardiovascular Disease

A critical 2026 randomized trial (1,695 patients) showed that metoprolol 100mg daily did NOT reduce COPD exacerbations, cardiovascular events, or death in COPD patients WITHOUT cardiovascular disease (HR 0.87,95% CI 0.73-1.05, P=0.14) 9. This definitively establishes that beta-blockers should not be used to treat COPD itself.

Practical Implementation Algorithm

Step 1: Identify cardiovascular indication

  • Is there heart failure, post-MI status, CAD, or arrhythmia requiring beta-blockade?
  • If NO → Do not prescribe metoprolol for COPD alone

Step 2: Assess COPD severity and type

  • True asthma with bronchospasm → Use extreme caution, consider alternatives first
  • COPD without asthma → Proceed with cardioselective agent

Step 3: Initiate cautiously

  • Start with lowest dose (metoprolol succinate 12.5-25mg daily)
  • Consider concurrent beta-2 agonist availability 5
  • Monitor for increased dyspnea, wheezing, or reduced exercise tolerance

Step 4: Titrate slowly

  • Increase dose every 2-4 weeks as tolerated
  • Monitor FEV1 if available, especially in severe COPD
  • Target evidence-based cardiovascular doses (up to 200mg daily for heart failure) 10

Common Pitfalls to Avoid

  1. Withholding beta-blockers entirely - This denies COPD patients proven mortality benefits for cardiovascular conditions 4, 6

  2. Using nonselective beta-blockers - Carvedilol causes greater FEV1 reduction than metoprolol or bisoprolol in COPD patients 7

  3. Prescribing for COPD management - Beta-blockers do not reduce COPD exacerbations in patients without cardiovascular disease 9, 11

  4. Confusing COPD with asthma - True severe asthma requires more caution; COPD is not an absolute contraindication 2

Bottom Line

Metoprolol succinate is safe and appropriate for COPD patients when there is a guideline-directed cardiovascular indication. Use cardioselective agents, start low, titrate slowly, and monitor respiratory status. Do not prescribe beta-blockers to treat COPD itself, as they provide no benefit for exacerbation prevention in the absence of cardiovascular disease.

References

Research

Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025

Research

Cardioselective beta-blockers for chronic obstructive pulmonary disease.

The Cochrane database of systematic reviews, 2005

Related Questions

Is Inderal (propranolol) cardioselective, and should it be avoided during a COPD exacerbation?
For an adult patient requiring a β‑blocker for hypertension, chronic heart failure, or stable angina, which is preferred—bisoprolol or metoprolol succinate—considering comorbidities such as chronic obstructive pulmonary disease or renal impairment?
In a patient with chronic heart failure and chronic obstructive pulmonary disease, which beta‑blocker is preferred: carvedilol (Coreg) or metoprolol?
In a patient with end-stage chronic obstructive pulmonary disease (COPD) who has mild sinus tachycardia and no atrial fibrillation, can metoprolol succinate (Toprol XL) be given to control heart rate?
In a 68-year-old female with chronic obstructive pulmonary disease, hypertension, and coronary artery disease who smokes half a pack per day, is taking aspirin, atenolol, atorvastatin, and a fluticasone propionate‑umeclidinium bromide‑vilanterol inhaler, walks half a mile without difficulty, has oxygen saturation of 93% on room air and mild wheezing, and is scheduled for an elective hysterectomy, what is the next step in preoperative management?
Is major depressive disorder with mixed features the same as cyclothymia?
What is the appropriate cefdinir dosage for a 2-year-old child weighing approximately 12 kg?
How should vitamin D3 (cholecalciferol) be prescribed at a dose of 800 IU orally once daily?
In an older male with leukocytosis (white blood cell count 18 × 10⁹/L), what work‑up is indicated and should prophylactic antibiotics be started while searching for the source?
How should I prescribe elemental calcium 600 mg twice daily?
How does duloxetine (Cymbalta) help with attention‑deficit/hyperactivity disorder and anxiety, and what instructions should be given for switching a patient from sertraline 25 mg to duloxetine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.